medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (5)


Within-patient temporal variance in MELD score and impact on survival prediction after TIPS creation

Gaba RC, Shah KD, CouturePM, Parvinian A, Minocha J, Knuttinen MG, Bui JT

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 797-802
Archivo PDF: 96.33 Kb.


RESUMEN

sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  2. Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, Meregaglia D, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36: 494-500.

  3. Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98: 1167-74.

  4. Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231: 231-6.

  5. Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, Berkes JL, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2012 [In press].

  6. Fitzgerald E, Charles HW, Teperman LW, Babb J, Kovacs S, Aquino T, Clark TW. Within-Patient Variance in MELD Prior to Elective TIPS. J Vasc Interv Radiol 2009; 20: S79.

  7. Gheorghe L, Iacob S, Iacob R, Gheorghe C, Popescu I. Variation of the MELD score as a predictor of death on the waiting list for liver transplantation. J Gastrointestin Liver Dis 2007; 16: 267-72.

  8. Gaba RC, Omene BO, Podczerwinski ES, Knuttinen MG, Cotler SJ, Kallwitz ER, Berkes JL, et al. TIPS for Treatment of Variceal Hemorrhage: Clinical Outcomes in 128 Patients at a Single Institution over a 12-Year Period. J Vasc Interv Radiol 2012; 23: 227-35.

  9. Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan D, Vedantham S, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17: 225-32.

  10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.

  11. Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. J Vasc Interv Radiol 2005; 16: 615-29.

  12. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-34.

  13. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-9.

  14. Bauer J, Johnson S, Durham J, Ludkowski M, Trotter J, Bak T, Wachs M. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl 2006; 12: 1544-51.

  15. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.




2020     |     www.medigraphic.com